We have developed the Oncopanel to detect mutations in solid tumors in 48 genes. We have also developed a Myeloid Panel to detect mutations in 52 genes associated with myeloid malignancies, including acute myeloid leukemia, myeloproliferative neoplasms, and myelodysplastic syndromes.
AKT1, ALK, APC, ATM, BMPR1A, BRAF, BRCA1, BRCA2, CDH1, CDK4, CDKN2A, CHEK2, CIC, EGFR, ERBB2 (HER2), ERBB3 (HER3), FUBP1, GNAQ, GNA11, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1 (MEK1), MET (HGFR), MLH1, MSH2, MSH6, MUTYH, NF1, NRAS, PALB2, PDGFRA, PIK3CA, PMS2, POLD1, POLE, PTEN, RET, ROS1, SDHA, SDHB, SDHC, SDHD, SMAD4, STK11, TP53.
ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DKC1, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KDM6A, KIT, KMT2A (MLL, PTDs only), KRAS, MPL, NF1, NPM1, NRAS, PHF6, PIGA, PRPF40B, PTEN, PTPN11, RAD21, RTEL1, RUNX1, SETD2, SF1, SF3A1, SF3B1, SH2B3, SMC1A, SMC3, SOCS3, SRSF2, STAG2, TERC, TERT, TET2, TP53, U2AF1, U2AF2, WT1, ZRSR2.
In British Columbia: Please refer to the Cancer Genetics Lab website.
Outside British Columbia: Please contact us for details and requisition forms.
The current turnaround time is 12-17 days from receipt of sample to mailing of report.
Please contact us for further details.